Effects of gabaergic drugs on reserpine-induced oral dyskinesia.
Recently we have described the antidyskinetic property of the GABA mimetic drugs valproic acid and topiramate on reserpine-induced oral dyskinesia. In this respect, oral dyskinesia has been associated with important neuropathologies. The present study investigates the effects of different doses of the GABA(A) agonist tetrahydroisoxazolopyridine (THIP), of the GABA(B) agonist baclofen as well as of the GABA(A) modulator diazepam on the manifestation of reserpine-induced orofacial dyskinesia. Male Wistar rats received two injections of vehicle or of 1mg/kg reserpine separated by 48 h. Twenty-four hours later, animals were acutely treated with vehicle or THIP (2, 4 or 8 mg/kg), baclofen (1, 2 or 4 mg/kg) or diazepam (1, 2 or 4 mg/kg) and were observed for quantification of oral dyskinesia and open-field general activity. In order to verify the effects of these drugs per se on spontaneous oral movements, male Wistar rats were acutely treated with vehicle, 8 mg/kg THIP, 4 mg/kg baclofen or 4 mg/kg diazepam and observed for quantification of oral dyskinesia. The two highest doses of THIP or of baclofen abolished the manifestation of reserpine-induced oral dyskinesia while the lowest dose of baclofen attenuated it. Diazepam did not modify reserpine-induced oral dyskinesia at any dose tested. The highest doses of these drugs did not modify spontaneous oral movements. Reserpine-induced decrease in open-field general activity was not modified by any of the doses of THIP and diazepam or by the two lowest doses of baclofen. The highest dose of baclofen potentiated the increase in the duration of immobility induced by reserpine. These results reinforce the involvement of GABAergic hypofunction in the expression of oral dyskinesias, and support the potential therapeutic use of THIP and baclofen in the treatment of oral dyskinesias.
Peixoto
Marcello F
MF
Department of Pharmacology, Escola Paulista de Medicina/UNIFESP, Edifício José Leal Prado, Rua Botucatu, 862 CEP 04023 062, São Paulo, SP, Brasil.
Araujo
Nilza P
NP
Silva
Regina H
RH
Castro
Juliana P M V
JP
Fukushiro
Daniela F
DF
Faria
Rulian R
RR
Zanier-Gomes
Patrícia H
PH
Medrano
Wladimir A
WA
Frussa-Filho
Roberto
R
Abílio
Vanessa C
VC
D000704:Analysis of Variance; D000818:Animals; D014150:Antipsychotic Agents / Q000633:toxicity*; D001418:Baclofen / Q000627:therapeutic use; D001522:Behavior, Animal / Q000187:drug effects; D003975:Diazepam / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000209:etiology; D018682:GABA Agents / Q000627:therapeutic use*; D046353:Immobility Response, Tonic / Q000187:drug effects; D007555:Isoxazoles / Q000627:therapeutic use; D008124:Locomotion / Q000187:drug effects; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012110:Reserpine / Q000633:toxicity*
D014150:Antipsychotic Agents; D018682:GABA Agents; D007555:Isoxazoles; D012110:Reserpine; D001418:Baclofen; C015542:gaboxadol; D003975:Diazepam